Free Trial

HC Wainwright Reaffirms "Buy" Rating for Prime Medicine (NYSE:PRME)

Prime Medicine logo with Medical background
Remove Ads

HC Wainwright reissued their buy rating on shares of Prime Medicine (NYSE:PRME - Free Report) in a research note issued to investors on Monday,Benzinga reports. They currently have a $10.00 price target on the stock. HC Wainwright also issued estimates for Prime Medicine's Q1 2025 earnings at ($0.35) EPS, Q2 2025 earnings at ($0.35) EPS, Q3 2025 earnings at ($0.29) EPS, Q4 2025 earnings at ($0.30) EPS, FY2025 earnings at ($1.28) EPS, FY2026 earnings at ($1.33) EPS, FY2027 earnings at ($1.33) EPS, FY2028 earnings at ($1.12) EPS and FY2029 earnings at ($0.75) EPS.

A number of other research analysts have also recently issued reports on PRME. Wedbush reiterated an "outperform" rating and issued a $12.00 target price on shares of Prime Medicine in a research note on Friday, February 28th. Chardan Capital reiterated a "buy" rating and issued a $15.00 price objective on shares of Prime Medicine in a research report on Monday. JMP Securities started coverage on Prime Medicine in a report on Tuesday, December 10th. They set an "outperform" rating and a $10.00 target price on the stock. StockNews.com raised Prime Medicine to a "sell" rating in a report on Tuesday, February 11th. Finally, Guggenheim reissued a "buy" rating and set a $18.00 price objective on shares of Prime Medicine in a report on Tuesday, December 3rd. One research analyst has rated the stock with a sell rating, nine have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $13.13.

Remove Ads

Check Out Our Latest Analysis on Prime Medicine

Prime Medicine Trading Down 0.4 %

Shares of Prime Medicine stock traded down $0.01 during mid-day trading on Monday, reaching $2.30. 1,225,802 shares of the stock were exchanged, compared to its average volume of 1,003,933. The company has a market cap of $301.67 million, a price-to-earnings ratio of -1.12 and a beta of 1.86. Prime Medicine has a fifty-two week low of $2.12 and a fifty-two week high of $8.58. The firm has a 50-day simple moving average of $2.82 and a 200 day simple moving average of $3.38.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of PRME. ProShare Advisors LLC raised its holdings in Prime Medicine by 24.6% during the fourth quarter. ProShare Advisors LLC now owns 22,186 shares of the company's stock worth $65,000 after acquiring an additional 4,375 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its stake in shares of Prime Medicine by 20.5% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 27,811 shares of the company's stock worth $81,000 after purchasing an additional 4,725 shares in the last quarter. Levin Capital Strategies L.P. boosted its holdings in shares of Prime Medicine by 7.1% in the 4th quarter. Levin Capital Strategies L.P. now owns 75,000 shares of the company's stock valued at $219,000 after buying an additional 5,000 shares during the last quarter. PEAK6 Investments LLC grew its stake in shares of Prime Medicine by 32.4% in the third quarter. PEAK6 Investments LLC now owns 45,013 shares of the company's stock valued at $174,000 after buying an additional 11,013 shares in the last quarter. Finally, American Century Companies Inc. acquired a new position in Prime Medicine during the fourth quarter worth $33,000. 70.37% of the stock is currently owned by institutional investors.

Prime Medicine Company Profile

(Get Free Report)

Prime Medicine, Inc, a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence.

Featured Articles

Analyst Recommendations for Prime Medicine (NYSE:PRME)

Should You Invest $1,000 in Prime Medicine Right Now?

Before you consider Prime Medicine, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prime Medicine wasn't on the list.

While Prime Medicine currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

7 Flying Car Stocks to Buy Before the Sector Really Takes Off

7 Flying Car Stocks to Buy Before the Sector Really Takes Off

Flying cars are coming sooner than you think! Investors are getting excited about this futuristic industry, and MarketBeat analyst Chris Markoch breaks down 7 flying car stocks poised to take off.

Related Videos

Archer Aviation: Sinking Now, Soaring Soon?
Marjorie Taylor Greene Bought THOUSANDS in Tesla Stock
Palantir’s Explosive Growth: Buy Now or Wait for a Dip?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads